Two drugs are now FDA-approved for a defined form of fatty liver disease with significant scarring. One targets metabolic pathways throughout the body. The other acts directly on a receptor involved in liver metabolism.
At The Liver Meeting in Denver this week, Novo Nordisk is putting Wegovy and Rezdiffra side by side in a real-world analysis. The comparison is genuinely interesting, but it is not a randomized clinical trial, and the distinction matters for how the findings should be interpreted.
The research examines short-term changes in liver enzymes, body weight and cardiometabolic markers among people receiving semaglutide or resmetirom in routine clinical practice.
It cannot establish which medicine is better at reversing advanced fibrosis or preventing liver failure. Those questions require different endpoints, longer follow-up and stronger evidence.
What Novo Is Bringing to Denver
The Liver Meeting, the annual congress of the American Association for the Study of Liver Diseases, takes place November 5–9, 2026, in Denver, Colorado.
Novo Nordisk’s headline comparative analysis, PLATINUM-Truveta, draws on de-identified electronic health records from 30 US healthcare systems.
The study includes 2,873 adults with MASH who initiated semaglutide 2.4 mg and 2,285 who initiated resmetirom.
Researchers examined changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), body weight, glycated hemoglobin (HbA1c), platelet counts and blood lipid measures at three and six months.
The analysis used records spanning June 2021 through March 2026, with exclusions for previous use of the study drugs, cirrhosis and other chronic liver diseases.
To address differences between treatment groups, the researchers used statistical methods including inverse probability of treatment weighting and generalized estimating equations.
Those methods may improve the comparison by accounting for measured differences, but they cannot recreate random treatment assignment.
The study was selected as a Poster of Distinction, a designation Novo says is awarded to the top 10% of submitted posters.
Its scheduled presentation is November 6, from 1 to 2 p.m. Denver time, as poster 2461.
Novo’s October 28 announcement described the study design without disclosing numerical comparative outcomes. Conference poster materials are also available through the company’s scientific portal, but preliminary observational findings still require scrutiny of the full methods and data.
That distinction is important because a conference comparison can generate useful clinical questions without establishing a definitive treatment hierarchy.
Two Approved MASH Drugs With Different Mechanisms
MASH, or metabolic dysfunction-associated steatohepatitis, is a progressive liver disease involving fat accumulation, inflammation and potentially damaging scar tissue.
It is frequently associated with obesity, type 2 diabetes and other cardiometabolic conditions.
As fibrosis advances, patients face increasing risks of cirrhosis, liver failure and liver-related complications.
Rezdiffra, developed by Madrigal Pharmaceuticals, was the first FDA-approved medicine specifically for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2 to F3.
It received accelerated approval on March 14, 2024.
Its active ingredient, resmetirom, is an oral thyroid hormone receptor-beta agonist. It activates pathways involved in hepatic fat metabolism, providing a liver-directed approach to treatment.
Wegovy followed with accelerated FDA approval for the same defined MASH fibrosis population on August 15, 2025.
Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist. Its effects include appetite regulation, weight reduction and improvements in metabolic measures, with potential liver benefits extending beyond weight loss alone.
The distinction is not that one medicine treats the liver and the other ignores it.
Rather, they approach the disease through different biological mechanisms, with different effects on body weight, glucose regulation and lipid metabolism.
Those differences may eventually help clinicians decide which treatment best suits an individual patient.
But choosing between two approved medicines is not the same as proving that one is universally superior.
What the Existing Clinical Trial Evidence Actually Shows
Both medicines received accelerated approval based on improvements in liver histology, including inflammation and fibrosis, rather than completed trials establishing reductions in long-term clinical events.
For Wegovy, the key evidence came from part 1 of the Phase 3 ESSENCE trial.
Among the first 800 randomized participants assessed at 72 weeks, fibrosis improved by at least one stage without worsening steatohepatitis in 36.8% of patients receiving semaglutide compared with 22.4% receiving placebo.
MASH resolution without worsening fibrosis occurred in 62.9% of semaglutide recipients versus 34.3% in the placebo group.
Those are meaningful differences in biopsy-based endpoints, but they are not proof that semaglutide prevents liver failure or transplantation over the long term.
ESSENCE continues into a second phase intended to evaluate liver-related clinical outcomes over 240 weeks, with results previously expected in 2029.
Rezdiffra’s approval was also supported by a randomized trial showing improvements in MASH resolution and fibrosis relative to placebo.
The FDA required continued investigation to verify the clinical benefit of those histological improvements.
Madrigal said in its November 3, 2026 financial update that it expects data from MAESTRO-NASH OUTCOMES in late 2027.
These two development programs provide evidence against their respective placebo groups. They do not establish a randomized comparison between semaglutide and resmetirom.
The trials also involved different populations, treatment durations and study conditions.
Putting percentages from separate studies next to one another would therefore be an unreliable way to rank the two medicines.
Two successful placebo-controlled trials do not automatically tell us which medicine is better when the drugs are compared with each other.
Why the Real-World Comparison Cannot Establish a Winner
PLATINUM-Truveta attempts to answer a different question from the original registration trials.
Instead of assigning treatments randomly, investigators examined what happened among patients who had already received one of the two drugs in routine healthcare.
That approach can reveal associations in a larger and potentially more varied clinical population.
It also creates several problems.
Patients prescribed semaglutide may differ systematically from those prescribed resmetirom in body weight, diabetes status, cardiovascular risk, disease severity or treatment history.
Even when researchers adjust for measured differences, some clinically relevant factors may be missing, incompletely recorded or inaccurately coded.
The study also required treatment persistence at its assessment timepoints, making it important to understand which patients remained eligible for analysis.
Patients who discontinue treatment or lack follow-up laboratory measurements may differ from those who remain in the dataset.
The endpoints create another limitation.
ALT and AST are useful indicators of liver-cell injury, but changes in these blood tests are not equivalent to directly demonstrating regression of fibrosis.
Similarly, improvements in weight or HbA1c may be clinically important without proving that a medicine more effectively prevents future cirrhosis.
The distinction matters particularly for semaglutide, which can produce substantial weight loss and changes in metabolic markers.
A favorable change in liver enzymes may accompany those improvements, but that does not by itself establish superiority in long-term liver outcomes.
Novo’s announcement explicitly acknowledges the possibility of unmeasured confounding, coding inaccuracies and limited follow-up.
Preliminary conference analyses may help clarify where the two treatments differ in the short term. They do not remove the fundamental limitations of the observational design.
Six months of liver enzymes cannot settle a disease that can take years to produce clinically serious scarring.
The Rest of Novo’s Liver Research Program
PLATINUM-Truveta is not the only liver research Novo is bringing to AASLD 2026.
Another retrospective study, RHODIUM-2, compares 2,479 patients with MASH who initiated semaglutide 2.4 mg against 70,702 patients who did not initiate the treatment.
It evaluates liver enzymes and cardiometabolic measures at three, six and twelve months.
Like PLATINUM-Truveta, RHODIUM-2 uses observational healthcare data, so its findings must be interpreted as associations rather than proof of causation.
Novo is also presenting a post hoc analysis of the ESSENCE trial focusing on participants with MASH and a body mass index below 27.
That subgroup matters because MASH is not exclusively a condition affecting people with obesity.
The ESSENCE subgroup presentation is scheduled for November 8.
Exploratory analyses can generate useful hypotheses about treatment effects in specific populations, but they should not be interpreted as independently powered trials unless their design supports that conclusion.
Elsewhere in Novo’s conference program, researchers will present findings involving investigational efruxifermin, an FGF21 analogue being studied in advanced liver disease.
Other presentations cover alcohol-related liver disease and experimental combinations involving zalfermin, cagrilintide and semaglutide.
These programs show how broad the competition in metabolic and inflammatory liver disease has become.
Some approaches focus primarily on metabolic regulation, others on liver-specific pathways or fibrosis-related biology.
The most effective future strategy may depend on which patients are being treated, how advanced their disease is and whether different mechanisms can safely complement each other.
The Commercial Stakes Are Already Growing
This is a market that both Novo Nordisk and Madrigal Pharmaceuticals have strong reasons to pursue.
On November 3, Madrigal reported third-quarter 2026 Rezdiffra net product revenue of $431.3 million, an increase of 50% from the same period a year earlier.
The company reported more than $1.1 billion in year-to-date Rezdiffra sales, crossing an important commercial milestone for a medicine launched in 2024.
As of September 30, Madrigal said more than 55,850 patients were on Rezdiffra, reflecting continued prescribing growth.
Those numbers illustrate the commercial potential of treatments directed at patients with diagnosed, clinically significant MASH.
But the addressable market is larger than the patients currently receiving treatment.
Novo cites estimates suggesting that more than 250 million people worldwide live with MASH and that nearly 90% remain undiagnosed.
These are prevalence and diagnosis estimates, not verified counts of individuals eligible for either approved medicine.
Eligibility depends on factors including fibrosis stage, the absence of cirrhosis, medical history, contraindications and individual clinical assessment.
The commercial contest is therefore not simply about which company persuades existing patients to switch medicines.
It is also about identifying patients earlier, establishing disease severity and helping clinicians choose an appropriate treatment.
That is where the difference between mechanisms becomes commercially important.
A patient with MASH, obesity and poorly controlled blood glucose may have different therapeutic priorities from a patient with similar liver fibrosis but without obesity.
Rezdiffra and Wegovy may eventually occupy different positions within individualized care pathways rather than competing as interchangeable treatments.
Researchers are also investigating how GLP-1-related therapies influence conditions beyond weight loss, including cardiovascular disease. As Grey Pepper’s coverage of cardiovascular real-world comparisons has emphasized, observational evidence must be separated from randomized trial results.
The wider investigation of peptide signaling in metabolic liver disease also includes research into mitochondrial-derived peptides, such as the experimental work discussed in our report on MOTS-c, exercise and fatty-liver biology.
None of those research directions eliminates the importance of proven clinical outcomes.
When the PLATINUM-Truveta poster is assessed in full, the most important questions are how well the treatment groups were balanced, how much follow-up data were available and whether differences in blood markers persisted after appropriate adjustment.
For the longer term, the questions are more demanding: which treatments prevent cirrhosis, liver-related hospitalization, transplantation and premature death?
The real competition in MASH may be decided less by one short-term laboratory marker than by which treatment offers the greatest benefit to the right patient over time.
For now, Novo’s AASLD presentation adds another piece to a growing evidence base.
It does not transform a retrospective comparison into a randomized trial, and it does not establish that either medicine is the universal winner.
The comparison is worth studying precisely because the unanswered questions remain clinically and commercially important.
Sources and Further Reading
- Novo Nordisk: New Liver Data Across Wegovy and Investigational Efruxifermin at AASLD 2026, October 28, 2026.
- Novo Nordisk Science Hub: AASLD 2026 Presentation Schedule and Conference Poster Materials.
- U.S. FDA: Approval of Wegovy for MASH With Moderate-to-Advanced Fibrosis, August 2025.
- U.S. FDA: First Treatment Approved for Patients With Liver Scarring Due to Fatty Liver Disease, March 14, 2024.
- Madrigal Pharmaceuticals: Third-Quarter 2026 Financial Results and Corporate Updates, November 3, 2026.
- American Association for the Study of Liver Diseases: The Liver Meeting 2026 Official Program.
